HVHomayoun Valafar

Homayoun Valafar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Homayoun Valafar has a total of 140 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Reformulation of the protein databank for real-time search of geometrical attributes of protein structures

    by Musa Azeem, Christopher Lee, Aaron Hein, Christopher Ott, Homayoun Valafar

    Introduction: In this study, we introduce the design and implementation of PDBMine, a large-scale, queryable platform for mining sequence-structure statistics from the Protein Data Bank (PDB). PDBMine enables rapid analysis of local conformational trends across proteins by extracting dihedral angles and sequence patterns at scale. In addition to the design and implementation of PDBMine, we also present results validating its ability to return structurally meaningful information. Methods: We first assess the accuracy of its dihedral angle distributions by comparing them to established Ramachandran space and verifying expected behaviors of residues such as glycine and proline. We then use PDBMine to analyze the statistical properties of amino acid subsequences of length k = 1 to 5. Results: Our findings reveal that longer k -mers exhibit significant departures from statistical independence, suggesting context-dependent constraints on amino acid co-occurrence. We also show that increasing local sequence context restricts dihedral angle variability, with longer k -mers producing distributions that more closely align with experimentally observed backbone geometries. Finally, we present a high-dimensional clustering method for grouping full-sequence dihedral conformations, enabling identification of dominant local structural motifs. Discussion: These results highlight PDBMine’s potential as a versatile tool for structure validation, statistical modeling, and probing the principles that govern sequence-structure compatibility in proteins.

  • Open Access

    Glycan Analysis of Serum and Breast Tissue Identifies Potential Biomarkers of Cancer Subtype and Severity

    by Nourine A.H. Kamili, Clay Elliot, Avery Funkhouser, Isam Alam, Julie Martin, Homayoun Valafar, Yi Lasanajak, Xuezheng Song, Connie M. Arthur, Jeffery Edenfield, et al.

    Breast cancer is the most prevalent cancer among women and one of the leading causes of cancer mortality. Early detection and accurate staging are essential for improving survival rates, yet current methods heavily rely on invasive biopsies. Glycoproteins, crucial biomarkers in various cancers, offer a minimally invasive diagnostic alternative. This pilot study employed MALDI-TOF mass spectrometry to analyze the glycomic profiles of breast tissue and serum samples from 39 breast cancer patients and 10 healthy controls. Over 300 unique glycans were identified, with significant elevations of high mannose glycans observed in malignant tissue and serum compared to healthy controls (p< 0.0001). Moreover, high-mannose glycan levels correlated with advanced cancer stages (p< 0.001) and poor differentiation grades (p< 0.05). HER2-positive and ER-negative tumors dis-played distinct glycosylation patterns, indicating potential molecular subtypes. Notably, serum levels of specific complex N-glycans, H3N5F1 and H4N5F1, declined significantly with disease progression, underscoring their potential as biomarkers. These findings suggest that glycomic profiling could revolutionize breast cancer diagnostics, enabling earlier detection, disease monitoring, and molecular subtyping. Further investigation is warranted to validate these biomarkers and elucidate their mechanistic roles in breast cancer pathogenesis.

  • Open Access

    Automated Aneurysm Boundary Detection and Volume Estimation Using Deep Learning

    by Alireza Bagheri Rajeoni, Breanna Pederson, Susan M. Lessner, Homayoun Valafar

    Background/Objective: Precise aneurysm volume measurement offers a transformative edge for risk assessment and treatment planning in clinical settings. Currently, clinical assessments rely heavily on manual review of medical imaging, a process that is time-consuming and prone to inter-observer variability. The widely accepted standard of care primarily focuses on measuring aneurysm diameter at its widest point, providing a limited perspective on aneurysm morphology and lacking efficient methods to measure aneurysm volumes. Yet, volume measurement can offer deeper insight into aneurysm progression and severity. In this study, we propose an automated approach that leverages the strengths of pre-trained neural networks and expert systems to delineate aneurysm boundaries and compute volumes on an unannotated dataset from 60 patients. The dataset includes slice-level start/end annotations for aneurysm but no pixel-wise aorta segmentations. Method: Our method utilizes a pre-trained UNet to automatically locate the aorta, employs SAM2 to track the aorta through vascular irregularities such as aneurysms down to the iliac bifurcation, and finally uses a Long Short-Term Memory (LSTM) network or expert system to identify the beginning and end points of the aneurysm within the aorta. Results: Despite no manual aorta segmentation, our approach achieves promising accuracy, predicting the aneurysm start point with an R2 score of 71%, the end point with an R2 score of 76%, and the volume with an R2 score of 92%. Conclusions: This technique has the potential to facilitate large-scale aneurysm analysis and improve clinical decision-making by reducing dependence on annotated datasets.

  • Open Access

    A deep learning software tool for automated sleep staging in rats via single channel EEG

    by Andrew Smith, Snezana Milosavljevic, Courtney J. Wright, Charlie A. Grant, Ana Pocivavsek, Homayoun Valafar

    Poor quality and poor duration of sleep have been associated with cognitive decline, diseases, and disorders. Therefore, sleep studies are imperative to recapitulate phenotypes associated with poor sleep quality and uncover mechanisms contributing to psychopathology. Classification of sleep stages, vigilance state bout durations, and number of transitions amongst vigilance states serves as a proxy for evaluating sleep quality in preclinical studies. Currently, the gold standard for sleep staging is expert human inspection of polysomnography (PSG) obtained from preclinical rodent models and this approach is immensely time consuming. To accelerate the analysis, we developed a deep-learning-based software tool for automated sleep stage classification in rats. This study aimed to develop an automated method for classifying three sleep stages in rats (REM/paradoxical sleep, NREM/slow-wave sleep, and wakefulness) using a deep learning approach based on single-channel EEG data. Single-channel EEG data were acquired from 16 rats, each undergoing two 24 h recording sessions. The data were labeled by human experts in 10 s epochs corresponding to three stages: REM/paradoxical sleep, NREM/slow-wave sleep, and wakefulness. A deep neural network (DNN) model was designed and trained to classify these stages using the raw temporal data from the EEG. The DNN achieved strong performance in predicting the three sleep stages, with an average F1 score of 87.6% over a cross-validated test set. The algorithm was able to predict key parameters of sleep architecture, including total bout duration, average bout duration, and number of bouts, with significant accuracy. Our deep learning model effectively automates the classification of sleep stages using single-channel EEG data in rats, reducing the need for labor-intensive manual annotation. This tool enables high-throughput sleep studies and may accelerate research into sleep-related pathologies. Furthermore, we provide over 700 h of expert-scored sleep data, available for public use in future research studies.


  • Open Access

    Aneurysm Analysis Using Deep Learning

    by Alireza Bagheri Rajeoni, Breanna Pederson, Susan M. Lessner, Homayoun Valafar

    Precise aneurysm volume measurement offers a transformative edge for risk assessment and treatment planning in clinical settings. Currently, clinical assessments rely heavily on manual review of medical imaging, a process that is time-consuming and prone to inter-observer variability. The widely accepted standard-of-care primarily focuses on measuring aneurysm diameter at its widest point, providing a limited perspective on aneurysm morphology and lacking efficient methods to measure aneurysm volumes. Yet, volume measurement can offer deeper insight into aneurysm progression and severity. In this study, we propose an automated approach that leverages the strengths of pre-trained neural networks and expert systems to delineate aneurysm boundaries and compute volumes on an unannotated dataset from 60 patients. The dataset includes slice-level start/end annotations for aneurysm but no pixel-wise aorta segmentations. Our method utilizes a pre-trained UNet to automatically locate the aorta, employs SAM2 to track the aorta through vascular irregularities such as aneurysms down to the iliac bifurcation, and finally uses a Long Short-Term Memory (LSTM) network or expert system to identify the beginning and end points of the aneurysm within the aorta. Despite no manual aorta segmentation, our approach achieves promising accuracy, predicting the aneurysm start point with an R 2 score of 71%, the end point with an R 2 score of 76%, and the volume with an R 2 score of 92%. This technique has the potential to facilitate large-scale aneurysm analysis and improve clinical decision-making by reducing dependence on annotated datasets.

  • Open Access

    Monitoring Opioid-Use-Disorder Treatment Adherence Using Smartwatch Gesture Recognition

    by Andrew Smith, Kuba Jerzmanowski, Phyllis Raynor, Cynthia F. Corbett, Homayoun Valafar

    The opioid epidemic in the United States has significantly impacted pregnant women with opioid use disorder (OUD), leading to increased health and social complications. This study explores the feasibility of using machine learning algorithms with consumer-grade smartwatches to identify medication-taking gestures. The research specifically focuses on treatments for OUD, investigating methadone and buprenorphine taking gestures. Participants (n = 16, all female university students) simulated medication-taking gestures in a controlled lab environment over two weeks, with data collected via Ticwatch E and E3 smartwatches running custom ASPIRE software. The study employed a RegNet-style 1D ResNet model to analyze gesture data, achieving high performance in three classification scenarios: distinguishing between medication types, separating medication gestures from daily activities, and detecting any medication-taking gesture. The model’s overall F1 scores were 0.89, 0.88, and 0.96 for each scenario, respectively. These findings suggest that smartwatch-based gesture recognition could enhance real-time monitoring and adherence to medication regimens for OUD treatment. Limitations include the use of simulated gestures and a small, homogeneous participant pool, warranting further real-world validation. This approach has the potential to improve patient outcomes and management strategies.

  • Open Access

    Pilot study: Initial investigation suggests differences in EMT-associated gene expression in breast tumor regions

    by Kylie L. King, Hamed Abdollahi, Zoe Dinkel, Alannah Akins, Homayoun Valafar, Heather Dunn

    Triple negative breast cancer (TNBC) is the most aggressive subtype and disproportionately affects African American women. The development of breast cancer is highly associated with interactions between tumor cells and the extracellular matrix (ECM), and recent research suggests that cellular components of the ECM vary between racial groups. This pilot study aimed to evaluate gene expression in TNBC samples from patients who identified as African American and Caucasian using traditional statistical methods and emerging Machine Learning (ML) approaches. ML enables the analysis of complex datasets and the extraction of useful information from small datasets. We selected four regions of interest from tumor biopsy samples and used laser microdissection to extract tissue for gene expression characterization via RT-qPCR. Both parametric and non-parametric statistical analyses identified genes differentially expressed between the two ethnic groups. Out of 40 genes analyzed, 4 were differentially expressed in the edge of tumor (ET) region and 8 in the ECM adjacent to the tumor (ECMT) region. In addition to statistical approach, ML was used to generate decision trees (DT) for a broader analysis of gene expression and ethnicity. Our DT models achieved 83.33 % accuracy and identified the most significant genes, including CD29 and EGF from the ET region and SNAI1 and CHD2 from the ECMT region. All significant genes were analyzed for pathway enrichment using MSigDB and Gene Ontology databases, most notably the epithelial to mesenchymal transition and cell motility pathways. This pilot study highlights key genes of interest that are differentially expressed in African American and Caucasian TNBC samples.


  • Open Access

    Toward Concurrent Identification of Human Activities with a Single Unifying Neural Network Classification: First Step

    by Andrew Smith, Musa Azeem, Chrisogonas O. Odhiambo, Pamela J. Wright, Hanim E. Diktas, Spencer Upton, Corby K. Martin, Brett Froeliger, Cynthia F. Corbett, Homayoun Valafar

    The characterization of human behavior in real-world contexts is critical for developing a comprehensive model of human health. Recent technological advancements have enabled wearables and sensors to passively and unobtrusively record and presumably quantify human behavior. Better understanding human activities in unobtrusive and passive ways is an indispensable tool in understanding the relationship between behavioral determinants of health and diseases. Adult individuals (N = 60) emulated the behaviors of smoking, exercising, eating, and medication (pill) taking in a laboratory setting while equipped with smartwatches that captured accelerometer data. The collected data underwent expert annotation and was used to train a deep neural network integrating convolutional and long short-term memory architectures to effectively segment time series into discrete activities. An average macro-F1 score of at least 85.1 resulted from a rigorous leave-one-subject-out cross-validation procedure conducted across participants. The score indicates the method’s high performance and potential for real-world applications, such as identifying health behaviors and informing strategies to influence health. Collectively, we demonstrated the potential of AI and its contributing role to healthcare during the early phases of diagnosis, prognosis, and/or intervention. From predictive analytics to personalized treatment plans, AI has the potential to assist healthcare professionals in making informed decisions, leading to more efficient and tailored patient care.


  • Top Cited Papers
    Open Access

    Integrating Omics Data and AI for Cancer Diagnosis and Prognosis

    by Yousaku Ozaki, Phil Broughton, Hamed Abdollahi, Homayoun Valafar, Anna V. Blenda

    Cancer is one of the leading causes of death, making timely diagnosis and prognosis very important. Utilization of AI (artificial intelligence) enables providers to organize and process patient data in a way that can lead to better overall outcomes. This review paper aims to look at the varying uses of AI for diagnosis and prognosis and clinical utility. PubMed and EBSCO databases were utilized for finding publications from 1 January 2020 to 22 December 2023. Articles were collected using key search terms such as “artificial intelligence” and “machine learning.” Included in the collection were studies of the application of AI in determining cancer diagnosis and prognosis using multi-omics data, radiomics, pathomics, and clinical and laboratory data. The resulting 89 studies were categorized into eight sections based on the type of data utilized and then further subdivided into two subsections focusing on cancer diagnosis and prognosis, respectively. Eight studies integrated more than one form of omics, namely genomics, transcriptomics, epigenomics, and proteomics. Incorporating AI into cancer diagnosis and prognosis alongside omics and clinical data represents a significant advancement. Given the considerable potential of AI in this domain, ongoing prospective studies are essential to enhance algorithm interpretability and to ensure safe clinical integration.